estrogen

Ethisterone (17α-Ethynyltestosterone) is a progestogen hormone.

Tamoxifen is an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).

Estradiol (E2) is a naturally occurring steroidal sex hormone that is essential for female fertility and maintenance of secondary sexual characteristics. Estradiol upregulates IL-6 expression through estrogen receptor beta (ERβ).

Letrozole (CGS 20267) is an Aromatase Inhibitor. The mechanism of action of letrozole is as an Aromatase Inhibitor.

Estrone sulfate sodium (17β-Estrone 3-sulfate) is an endogenous steroid and an estrogen ester that is biologically inactive. It is converted by steroid sulfatase into estrone . Estrone sulfate sodium has been investigated as a ligand for targeting organic anion transporting polypeptides f

Fadrozole hydrochloride (CGS 16949A) is a model aromatase inhibitor that effectively suppresses estrogen production in fish ovaries.

Estrogen receptor antagonist 8 acts as an estrogen receptor (ER) antagonist with anti-uterine activity and potential anti-tumorigenic activity and can be used to study ovarian dysfunction.

Estrogen receptor modulator 1 causes regression of Tamoxifen-resistant, hormone-independent xenograft tumors. Estrogen receptor modulator 1 is an orally active and selective estrogen receptor modulator (SERM) (pIC50: 0.46).

Conjugated estrogens are medicine that contains a mixture of estrogen hormones. It is used to treat moderate to severe hot flashes, changes in and around the vagina, and other symptoms of menopause or low amounts of estrogen. Conjugated estrogens tablet i

Estrogen receptor-agonist-1 (compound 4e) is an estrogen receptor (ER) agonist that binds to ERα with high affinity.

Estrogen receptor modulator11 (Compound 27) is a tetrahydroisoquinoline derivative. It exhibits affinity for the estrogen receptor (ER), with IC50 values of 285 nM for ERα and 421 nM for ERβ. Estrogen receptor modulator11 does not demonstrate antagonist activity in MCF-7 cell assays.

Estrogen receptor modulator 6 (compound 3a) is a highly specific and potent agonist of the estrogen receptor (ER) β, exhibiting remarkable affinity (K i = 0.44 nM) and impressive 19-fold selectivity for ERβ over ERα, as evidenced by its affinity (K i = 8.4 nM).

Estrogen receptor-IN-1 (compound 16) is an effective estrogen receptor (ER) inhibitor with IC50 values of 13 μM for ERα and 5 μM for ERβ, respectively [1].

Estrogen Receptor Antagonist 7 (Compound 13) is a potent antagonist of estrogen receptors (ER), demonstrating antiproliferative effects against breast and ovarian cancer cells, along with anticancer and anti-uterotrophic activities [1].

Estrogen receptor β antagonist 2 is a selective and potent estrogen receptor β (ERβ) antagonist, with an IC50 of 109.10 μM for ERα and 0.63 μM for ERβ.

Estrogen receptor α antagonist 1 (compound 35) is a highly selective antagonist of estrogen receptor α, demonstrating an IC50 of 0.02 μM against this receptor and also affecting estrogen receptor β. This compound is utilized in tumor research.

Estrogen receptor antagonist 5 is a potent inhibitor of the Estrogen receptor, a ligand-activated transcriptional regulatory protein that interacts with endogenous estrogens and mediates various biological effects. [Estrogen receptor antagonist 5] shows promise for studies on metastatic disease.

Estrogen receptor antagonist 6, also known as Compound 166, is a potent antagonist of the ligand-activated transcriptional regulatory protein Estrogen receptor, which interacts with endogenous estrogens to mediate various biological effects.

Estrogen Receptor Antagonist 4 is a potent inhibitor of the estrogen receptor (ER), crucial for regulating cell growth, differentiation, and apoptosis. This compound holds promise for cancer research[1].

Estrogen receptor antagonist 2 is a selective down-regulator of the estrogen receptor, with research potential for breast cancer disease. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development.

Estrogen receptor antagonist 1 is a potent inhibitor of the estrogen receptor, demonstrating research potential in breast cancer disease.

Estrogen receptor antagonist 3 is a potent degradation agent of the estrogen receptor (ER). Estrogen signaling systems regulate cell growth, differentiation, and apoptosis, and estrogen receptor antagonist 4 has shown potential for cancer research.

Estrogen Receptor Modulator 7 is a potent modulator of estrogen receptors, utilized in cancer research [1].

Estrogen Receptor Modulator 8 (compound 4) is an orally active inhibitor targeting Estrogen Receptor ERR α with potent efficacy (IC50 = 0.437 nM in MCF-7 cells) and effectively hampers MCF-7 cell proliferation (IC50 = 0.1 nM) [1].